PET scout: A valuable technology in pediatric <sup>18</sup>F-FDG PET/CT imaging.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 41099836.
- Also identified by DOI 10.1007/s00259-025-07554-y.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To explore the potential value of PET Scout technology for optimizing the examination workflow of pediatric ¹⁸F-FDG PET/CT. A total of 527 children who underwent PET/CT imaging were prospectively divided into a standard-dose group (3.7 MBq/kg, n = 391) and a low-dose group (2.5 MBq/kg, n = 136). A body PET Scout scan (10 s/bed) was performed before PET/CT scan. Visual analysis of Scout MIP images identified improper positioning, radioactive contamination, and lesions outside the normal range (skull base to mid-thigh) as abnormal findings. Abnormal detection rates and lesion detection performance were compared between the two groups. PET Scout identified abnormal detections in 9.7% (51/527) of patients, including out-of-range lesions (27 cases), contamination (19 cases), and postural abnormalities (5 cases). There was no significant difference in the abnormal detection rate (9.2% vs. 11.0%, χ² = 0.383, P = 0.536) and in the area under the ROC curve (AUC) of lesion detection performance (0.9086 vs. 0.9104; Z = -0.0953, P = 0.924) between the standard-dose group and the low-dose group. Optimal SUVmax cut-offs were 3.05 (sensitivity 82.9%; specificity 85.4%) and 3.25 (sensitivity 81.6%; specificity 87.0%) for the standard and low-dose groups, respectively. PET Scout enables early detection of abnormalities and real-time workflow optimization. The technology is comparable in lesion detectability at low-dose and standard-dose imaging, and supports flexible application under different dose strategies.
Medical subject headings
- Fluorodeoxyglucose F18
- Positron Emission Tomography Computed Tomography